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Relation between Intracavernosal Dose of Prostaglandin Pge 1 and Mean 
Duration of Erection in Men with Different Underlying Causes of Erectile 
Dysfunction
Aim To analyze differences in effect of intracavernosally applied alprostadil (pros-
taglandin PGE 1) on men with different underlying causes of erectile dysfunction.
Methods Forty eight men with erectile dysfunction lasting for at least six months 
were stratified according to the etiology of erectile dysfunction into one of 4 
groups comprising 12 patients. The groups were the following: psychogenic, ar-
teriogenic, veno-occlusive, and neurological erectile dysfunction group. All men 
filled out International Index of Erectile Function (IIEF)-5 questionnaire, which 
is a 5-question version of International Index of Erectile Function Questionnaire, 
underwent clinical examination including neurological assessment, were tested for 
nocturnal penile tumescence, and had Doppler color sonography of penile arter-
ies. Intracavernosal alprostadil was then applied to the patients, starting with a 
5 μg dose and then increased in 5 μg increments until the final dose of 20 μg was 
reached. We measured the time from the moment of application until the start 
of erection and time of erection duration. For statistical analysis, non-parametric 
Friedman test for significant differences between repeated measurements in small 
groups and Wilcoxon test for differences between doses were used.
Results Significant relation was found between the applied dose of intracaverno-
sal alprostadil and the duration of erection in all 4 groups of men with erectile 
dysfunction. In patients with arteriogenic erectile dysfunction, mean (±standard 
deviation) duration of erection for consecutive doses of alprostadil 5μg, 10 μg, 15 
μg, and 20 μg were 40.0 ± 20.6, 54.6 ± 23.6, 65.0 ± 29.6, and 82.1 ± 35.4 minutes, 
respectively, with significant increase for each dose. In patients with veno-occlusive 
dysfunction, mean durations of erection significantly increased from 8.2 ± 7.8 min-
utes at 10 μg to 17.3 ± 9.5 minutes at 20 μg. In patients with neurogenic erectile 
dysfunction, mean durations of erection were 40.4 ± 16.6, 61.7 ± 24.7, 82.5 ± 34.4, 
and 101.0 ± 28.5 minutes respectively, with significant increase for each dose. In 
patients with psychogenic erectile dysfunction, mean durations of erection were 
32.4 ± 15.4, 45.8 ± 15.1, 69.9 ± 23.5, and 98.3 ± 37.9 minutes respectively, with a 
significant increase for each dose.
Conclusion Men with different underlying cause of erectile dysfunction show dif-
ferent response to the intracavernosally applied alprostadil. In order to achieve the 
optimal result, the treatment should be started with the smallest doses which are 
gradually increased until the maximum effect is reached.
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Erectile dysfunction is a condition that affects a 
many men. Epidemiological studies have shown 
that more than half of the men between 40 and 70 
years have at least some degree of erectile dysfunc-
tion (1). This is also a social problem, since it neg-
atively affects the quality of the relationship with 
their partner. The treatment of this condition is 
very important for both the affected man and his 
partner and should be started as soon as possible (2).
In recent years, orally effective agents (phospho-
diesterase type 5 inhibitors) became the most fre-
quently prescribed treatment for erectile dysfunc-
tion (3-7). However, some men do not respond to 
oral treatment or have contraindications for such 
a treatment. For this group of men, intracaverno-
sal application of vasoactive agents is the second 
best choice, which is still widely used (8). Prosta-
glandin PGE1 (alprostadil) was proven to be the 
safest vasoactive agent, as well as an effective one 
(8-13). In order to maximize the effects and min-
imize the potentially dangerous side effects, such 
as priapism, it is very important to carefully select 
the starting dose of this medication in men with 
different underlying causes of erectile dysfunc-
tion. The aim of this study was to evaluate the re-
sponse to different doses of intracavernosally ap-
plied alprostadil in this population of men.
Subjects and methods
Patients
Forty eight men with moderate to severe erectile 
dysfunction lasting for at least six months were 
included in the study. The study was done entire-
ly in our department between January 2002 and 
June 2005 and was not funded by any outside 
source. The patients were selected among the pa-
tients who had visited our outpatient clinic for 
erectile dysfunction and the first 12 patients that 
fulfilled the criteria for inclusion into one of the 
four groups were selected. The primary inclusion 
criterion was the score of less than 21 on the 5-
item International Index of Erectile Function 
(IIEF-5) questionnaire (14). From all patients, a 
detailed history was taken and a clinical examina-
tion performed, including a neurological evalua-
tion. Also, the presence or absence of nocturnal 
penile tumescence was confirmed using the snap-
gauge band (15). In further evaluation, Doppler 
color sonography of the penile arteries was per-
formed. We measured two parameters, peak sys-
tolic velocity and end diastolic velocity. Peak sys-
tolic velocity above 25 cm/s indicated a normal 
arterial inflow. End diastolic velocity below 5 
cm/s was considered normal, excluding the pres-
ence of veno-occlusive dysfunction (16). In cases 
with elevated end diastolic velocity, pharmaco-
cavernosography was performed to confirm or ex-
clude the presence of veno-occlusive dysfunction.
Patients were stratified into one of the 4 
groups with 12 patients in each. Patients with 
normal penile sonography, present nocturnal tu-
mescence, and absent neurological deficits were 
stratified in the group with psychogenic cause of 
erectile dysfunction (17). Patients with low peak 
systolic velocity, normal end diastolic velocity on 
sonography, absent nocturnal tumescence, and 
normal neurological findings were stratified into 
the group with arteriogenic erectile dysfunction 
(16). Patients with veno-occlusive dysfunction, 
confirmed by pharmacocavernosography, nor-
mal peak systolic velocity, elevated end diastolic 
velocity, absent nocturnal tumescence, and nor-
mal neurological findings were stratified in the 
group with veno-occlusive dysfunction (16). The 
last group was formed of patients who had nor-
mal penile sonography, absent nocturnal penile 
tumescence, a clinically evident neurological le-
sion in the S2-S4 region, and absent bulbocaver-
nosus reflex. To be sure that the underlying cause 
of erectile dysfunction in this group of patients 
was neurological, only the patients after the trau-
matic lesion of the lower spine with no residual 
reflex erections were included (18,19).
Procedure
Alprostadil (Caverject, Pfizer, New York, NY, 
USA) was applied intracavernosally to each pa-
tient in increasing doses. The starting dose was 5 
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μg and the doses were increased by 5 μg each time 
until the final dose of 20 μg was reached or the 
erections became too long (more than 120 min-
utes), allowing a possibility of prolonged erection 
by further increase in the dose. The applications 
were done not less than 3 days and not more 
than 14 days apart, by the same person. We used 
28-gauge needles and the application was done 
laterally on the shaft of the penis, 1 cm behind 
the glans penis (20). We measured the time from 
the moment of the application until the start of 
the erection and then until the end of the erec-
tion. The start of the erection was determined as 
20% increase in the penile diameter, while the 
end of erection was confirmed when the penile 
diameter returned to the starting value (21). The 
measurement of the penile diameter was made by 
previously designed frames. The duration of the 
erections was calculated as the time from the 
start till the end of the erection.
The study was approved by the medical eth-
ics committee of the Republic Slovenia and all 
procedures were in accordance with the Helsinki 
declaration and good clinical practice principles.
Statistical analysis
Data were presented as mean and standard de-
viations (SD), using the Statistical Package for 
the Social Sciences, version 10.0.1 for Windows 
(SPSS Inc., Chicago, IL, USA). Although the 
varialbles were normally distributed, due to the 
small number of subjects per group, non-para-
metric tests were used to determine the relation-
ship between the doses and the duration of the 
erections – Friedman test for significant differ-
ences between repeated measurements within 
groups and Wilcoxon signed rank test for differ-




Mean age±SD of the patients in this group was 
59.3 ± 11.1 years. Mean peak systolic velocity in 
this group was 20.3 ± 3.6 cm/s, and mean end 
diastolic velocity was 0.3 ± 0.8 cm/s. Mean du-
ration of erection significantly increased with 
the increasing dose, from 40.0 ± 20.6 at 5 μg to 
82.1 ± 35.4 at 20 μg (Friedman test, P<0.001; 
Figure 1A). Wilcoxon signed rank test revealed 
a significant increase in duration of erection with 
each higher dose (Figure 1A).
Veno-occlusive dysfunction
Patients in this group had a mean age of 
37.6 ± 22.0 years, mean peak systolic velocity of 
29.6 ± 2.4 cm/s, and mean end diastolic veloci-
ty of 8.2 ± 0.7 cm/s. Some of the patients in this 
group did not achieve an erection after the appli-
cation of certain doses (6 patients at 5 μg, 5 pa-
tients at 10 μg, 3 patients at 15 μg, and 2 patients 
at 20 μg). In statistical analysis, the value of zero 
(0) minutes was used for these patients. Mean 
duration of the erections increased 5.8 ± 6.7 min-
utes at the 5 μg to 17.3 ± 9.5 minutes at the 20 μg 
(Friedman test, P = 0.005; Figure 1B). Wilcoxon 
signed rank test revealed significant increase in 
duration of erection with highest dose, but not 
in low dose range of alprostadil (Figure 1B).
Neurogenic erectile dysfunction
The mean age of patients in this group was 
43.1 ± 8.0 years, mean peak systolic velocity was 
33.6 ± 4.3 cm/s, and mean end diastolic veloc-
ity –0.3 ± 0.7 cm/s. Two of the patients in this 
group did not receive 20 μg dose because their re-
sponse to 15 μg dose was so intense (120 and 150 
minutes duration of erection) that there was a rea-
sonable fear that 20 μg dose could result in a dan-
gerously prolonged erection or even priapism.
The erection duration significantly increased 
from average of 40.4±16.6 minutes at 5 μg to 
101.0±28.5 minutes at 20 μg (Friedman test, 
P<0.001; Figure 1C). Wilcoxon signed rank test 
significant increase in duration of erection with 
higher each dose of alprostadil (Figure 1C).
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Psychogenic erectile dysfunction
The patients in this group were on the average 
38.1 ± 7.6 years old and had a mean peak systol-
ic velocity of 34.3 ± 3.4 cm/s, and mean end dia-
stolic velocity of -0.3 ± 0.9 cm/s.
Mean duration of erections in this group 
increased from 32.4±15.4 minutes at 5 μg to 
98.3±37.9 minutes at 20 μg (Friedman test, 
P<0.001; Figure 1D). Again, Wilcoxon signed 
rank test revealed a significant increase in duration 
of erection with each higher dose of alprostadil.
During the whole study, we had no side ef-
fects, there was not a single case of priapism, and 
no reports of any significant local hematomas. 
Only a few patients reported mild local pain at 
the injection site, but the pain was not serious 
enough for patients to quit the study.
Discussion
Our study showed a statistically significant in-
crease in the duration of the erections with in-
crease in the dose of applied alprostadil in all the 
groups. There were some differences in the re-
sponse between the groups with different under-
lying causes of erectile dysfunction. The stron-
gest response was in the group with neurogenic 
erectile dysfunction, where lower starting doses 
are recommended to avoid a possible prolonged 
erection or priapism. The highest doses should 
be cautiously used in this group of the patients. 
On the other hand, the response was smaller in 
the group with veno-occlusive dysfunction and 
some of the patients in this group showed no re-
sponse even with the highest doses. The lack of 
the response at lower doses does not, however, 
rule out the possibility of an effective treatment 
with higher doses. Therefore, administration of 
high doses of intracavernosal alprostadil should 
be considered before other more aggressive forms 
of treatment.
Our results are well in accordance with pre-
vious knowledge about the effects of the intra-
cavernosal use of alprostadil in men with erectile 
dysfunction. Many studies dealt with the effica-
cy of self-administered vasoactive drugs, mainly 
comparing the overall efficacy of different vaso-
active substances. As for the overall efficacy, side 
effects, and tolerability of this type of treatment, 
our results are well in accordance with these oth-
er studies (8,11,12,21). To our knowledge, our 
study was the first detailed analysis on treatment 
response in men with different underlying causes 
of erectile dysfunction, so we can only rely on our 
Figure 1. Duration of erection in men with dif ferent causes of erec-
tile dysfunction (mean±SD). (A) arteriogenic erectile dysfunction; 
(B) veno-occlusive erectile dysfunction; (C) neurogenic erectile 
dysfunction; (D) psychogenic erectile dysfunction. P values represent 
results of comparisons in erection duration with a first lower dose 
(Wilcoxon signed rank test).
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results. The drawback of our study is a relative-
ly small number of patients, which is why larger 
studies are needed to confirm the external valid-
ity of our conclusions.
Our study shows that the application of in-
tracavernosal alprostadil remains an effective and 
safe treatment of erectile dysfunction. The start-
ing doses should be adjusted individually accord-
ing to the suspected underlying cause of erectile 
dysfunction, in order to avoid possible prolonged 
erections or priapism. The relation between the 
higher subsequent doses and the duration of erec-
tions has proven to be positive linear, so we can 
expect longer erection times with the increase in 
the dose in all the patients. If the increase in the 
dose is made in small increments, one can avoid 
the possible side effects. In our study we did not 
observe any side effects, such as prolonged erec-
tion or priapism.
Intracavernosal application of vasoactive 
agents remains one of the modalities for the 
treatment of erectile dysfunction. In the era of 
orally effective agents, it is considered to be a sec-
ondary treatment, used mainly when oral agents 
yield no response or are contraindicated. Never-
theless, intracavernosal injections are still widely 
used and knowledge about the exact effects of dif-
ferent doses is important if we want to satisfy our 
patients’ need for an adequate treatment without 
the risk of potentially dangerous side effects.
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